Innovation reports positive top-line results from Phase II trial of IBD drug

Innovation Pharmaceuticals has reported positive top-line results from a Phase II clinical trial of brilacidin in patients with inflammatory bowel disease (IBD) types known as ulcerative proctitis and ulcerative proctosigmoiditis (UP/UPS).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news